Junjie Shao

Gilteritinib Suppresses Hepatocellular Carcinoma Cells in Association with Reduced Calpain-1 Expression and Inhibition of STAT3/AKT Signaling

Background/Objectives: Hepatocellular carcinoma (HCC) is a leading cause of cancer-associated mortality worldwide, and current targeted therapeutic options remain inadequate. Gilteritinib, a clinically approved tyrosine kinase inhibitor, has shown antitumor activity in hematologi...